Sector

Healthcare

One of the most prominent practices in Europe, on a growing resilient sector, underpinned by constant innovation in biotech and medtech, and long-term demand for healthcare services.

Bryan, Garnier & Co's insights and news

Read the latest news, reports and newsletters from Europe’s Growth Investment Bank to find out more about current trends impacting investment banking activity and company performance.

Healthcare transactions

Bryan, Garnier & Co offers a complete range of investment banking services, from growth financing to mergers and acquisitions.

Bryan, Garnier & Co acts as Financial Advisor & Placement Agent on Abivax’s EUR 130 million Cross-over Financing

Bryan, Garnier & Co acts as Sole Financial Advisor to Selfapy, one of the leading providers in digital therapeutics for mental health disorders in Germany, on its growth financing from strategic investor Medice Arzneimittel and existing shareholders

Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on Egetis Therapeutics’ Nasdaq Stockholm SEK 210 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Bookrunner on Oncodesign Precision Medicine’s EUR 8 million Follow-on Offering & IPO on Euronext Growth Paris

Bryan, Garnier & Co acts as Sole Financial Advisor to XVIVO on the acquisition of the Machine & Perfusion division from Avionord S.r.l.

Bryan, Garnier & Co acts as Joint Global Coordinator & Joint Bookrunner on Nicox’ Euronext Paris EUR 10 million Follow-on Offering & Warrants issuance

Bryan, Garnier & Co acts as Joint Bookrunner on Valneva’s Nasdaq and Euronext Paris EUR 102.9 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Global Coordinator and Joint Bookrunner on Abivax’s EUR 49 million Cross-over Financing

Bryan, Garnier & Co acts as Sole Financial Advisor to Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, on its first €21 million closing of its oversubscribed Fundraising

Bryan, Garnier & Co acts as Sole Financial Advisor to Oncodesign on the sale of its CRO activities to Elyan Partners for €100m and the concomitant spin-off of its Biotech/AI activities

Bryan, Garnier & Co acts as Sole Global Coordinator & Sole Bookrunner on GeNeuro EUR 7.7 million Follow-On Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of Grundium Oy on the sale of a majority stake to EW Healthcare Partners

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on Aelis Farma’s Euronext Paris EUR 25m Initial Public Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to clinical-stage biologics company BiosanaPharma on its global strategic partnership with Alvotech

Bryan, Garnier & Co acts as Sole Financial Advisor to Wandercraft on its $45 million Fundraising

Bryan, Garnier & Co acted as Sole Financial Advisor to the shareholders of CMN on its partnership with MBO & Co